Launch week offerEnds in00h00m00s

annual Promonthly Pro

Fabio Puglisi

Head of the Unit of Medical Oncology and Cancer Prevention

Italy

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Italy Professors in Cancer Biology Cancer Biology professors in Italy

About

Fabio Puglisi is the Head of the Unit of Medical Oncology and Cancer Prevention at CRO di Aviano, IRCCS, National Cancer Institute, Italy. His research interests include immune checkpoint inhibitors in breast cancer, genetic mutations in melanoma, and precision oncology in triple-negative breast cancer. Additionally, he focuses on therapeutic approaches in oncogene-addicted non-small cell lung cancer and the impact of social media in medical oncology education.

Articles (27)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (22)

Carmine Valenza

European Institute of Oncology

ITALY

Fabio Puglisi

Research Interests

Make your next move.

Explore related searches

About

Articles (27)

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions

Probe-Based Confocal Laser Endomicroscopy During Immune Checkpoint Inhibitor Therapy: A Translational Framework Linking Intestinal Barrier Function, Microbiota, and Clinical Outcomes

Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease

Ten-year survival of women with invasive breast cancer by stage, molecular subtype, and grade combined: a population-based study

Clinical Validity of Imatinib Therapeutic Drug Monitoring in a Real-World Italian Cohort of Gastrointestinal Stromal Tumors and the Role of Patients’ Sex

Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial

LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients

Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches

Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2− Breast Cancer: A Systematic Review

Clinical, Histopathological, Dermoscopic Features, and <i>BRAF</i>, <i>NRAS</i>, and Cell Cycle Genes’ Mutation Status in Cutaneous Melanoma

Novel De Novo BRCA2 Variant in an Early-Onset Ovarian Cancer Reveals a Unique Tumor Evolution Pathway

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them

Role of Social Media for Medical Oncologists and Medical Oncology Fellows (SMARTY): An Italian Cross-Sectional Study

Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer

A New Model for Bone Health Management in Postmenopausal Early Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy—The Predict & Prevent Project

Idiosyncratic Drug-Induced Liver Injury and Trastuzumab Deruxtecan in Breast Cancer: A Case Report

Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology

Managing sexual health challenges in breast cancer survivors: A comprehensive review

Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial

Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring

Hereditary Cancer Syndromes: A Comprehensive Review with A Visual Tool

Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial

Nutritional Management of Oncological Symptoms: A Comprehensive Review

A Randomized Clinical Trial Investigating an Integrated Nursing Educational Program to Mitigate Chemotherapy-Induced Nausea and Vomiting in Cancer Patients: The NIV-EC Trial

Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations

Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer

Collaborators (22)

Carmine Valenza

Maria Antonietta Pizzichetta

Riccardo Dolcetti

Giuseppe Palmieri

G. Roccuzzo

Armando Orlandi

Lucia Del Mastro

Antonio Cossu

Daniela Massi

Luca Licata

Alberto Zambelli

CARMINE DE ANGELIS

Kyung Hae Jung

Vincenzo Canzonieri

ida paris

Renato Cannizzaro

Giampaolo Bianchini

Massimo Cristofanilli

Daniela Califano

Rossana Roncato

alessandra bearz

Rossana Berardi

Make your next move.